S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:VRAY

ViewRay (VRAY) Stock Forecast, Price & News

$2.99
+0.11 (+3.82%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.86
$3.05
50-Day Range
$2.42
$4.10
52-Week Range
$2.39
$8.25
Volume
2.73 million shs
Average Volume
2.28 million shs
Market Capitalization
$539.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

ViewRay logo

About ViewRay

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Headlines

ViewRay (NASDAQ:VRAY) Price Target Cut to $7.00
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRAY
Employees
267
Year Founded
N/A

Sales & Book Value

Annual Sales
$70.12 million
Book Value
$0.82 per share

Profitability

Net Income
$-110.05 million
Net Margins
-148.47%
Pretax Margin
-148.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
171,796,000
Market Cap
$539.58 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/22/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

191st out of 1,416 stocks

Electromedical Equipment Industry

4th out of 29 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













ViewRay (NASDAQ:VRAY) Frequently Asked Questions

Is ViewRay a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ViewRay stock.
View analyst ratings for ViewRay
or view top-rated stocks.

When is ViewRay's next earnings date?

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for ViewRay
.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) issued its quarterly earnings results on Thursday, May, 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The firm had revenue of $18.88 million for the quarter, compared to analysts' expectations of $15.62 million. ViewRay had a negative trailing twelve-month return on equity of 76.00% and a negative net margin of 148.47%. The firm's quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS.
View ViewRay's earnings history
.

What guidance has ViewRay issued on next quarter's earnings?

ViewRay updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $84.00 million-$104.00 million, compared to the consensus revenue estimate of $94.73 million.

What price target have analysts set for VRAY?

4 analysts have issued 12-month price objectives for ViewRay's stock. Their forecasts range from $7.00 to $7.00. On average, they expect ViewRay's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 134.1% from the stock's current price.
View analysts' price targets for ViewRay
or view top-rated stocks among Wall Street analysts.

Who are ViewRay's key executives?
ViewRay's management team includes the following people:
  • Mr. Scott William Drake, Pres, CEO & Director (Age 54, Pay $1.41M) (LinkedIn Profile)
  • Mr. Zachary William Stassen, Chief Financial Officer (Age 43, Pay $413.08k) (LinkedIn Profile)
  • Dr. James F. Dempsey, Chief Scientific Officer (Age 51, Pay $523.09k)
  • Ms. Ashley Kluth, Sr. Mang. of Investor Relations
  • Mr. Robert S. McCormack, Sr. VP, Gen. Counsel & Corp. Sec.
  • Karen Hackstaff, VP of Marketing
  • Mr. Robert Michael Fuchs, Chief HR Officer (Age 55)
  • Dr. Martin Fuss, Chief Medical Officer
  • Mr. Paul Ziegler Jr., Chief Commercial Officer
  • Ms. Amanda Sequira, Sr. VP of Clinical, Quality & Regulatory (Age 44)
What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay CEO Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among ViewRay's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.71%), Vanguard Group Inc. (4.91%), State Street Corp (2.41%), Candriam Luxembourg S.C.A. (0.96%), Dimensional Fund Advisors LP (0.86%) and Northern Trust Corp (0.84%). Company insiders that own ViewRay stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends for ViewRay
.

Which major investors are selling ViewRay stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Calamos Advisors LLC, Sei Investments Co., Russell Investments Group Ltd., Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., UBS Group AG, and Peregrine Capital Management LLC. Company insiders that have sold ViewRay company stock in the last year include Influence Ltd Strong, and International Ltd Fosun.
View insider buying and selling activity for ViewRay
or view top insider-selling stocks.

Which major investors are buying ViewRay stock?

VRAY stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Renaissance Technologies LLC, Engineers Gate Manager LP, BlackRock Inc., Kahn Brothers Group Inc., GSA Capital Partners LLP, and Qube Research & Technologies Ltd. Company insiders that have bought ViewRay stock in the last two years include Brian K Roberts, Caley Castelein, Scott William Drake, Susan C Schnabel, and Zachary William Stassen.
View insider buying and selling activity for ViewRay
or or view top insider-buying stocks.

How do I buy shares of ViewRay?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $2.99.

How much money does ViewRay make?

ViewRay has a market capitalization of $539.58 million and generates $70.12 million in revenue each year. The company earns $-110.05 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does ViewRay have?

ViewRay employs 267 workers across the globe.

What is ViewRay's official website?

The official website for ViewRay is www.viewray.com.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at (440) 703-3210, via email at [email protected], or via fax at 800-417-3459.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.